Robin et al., 2006 - Google Patents
Stromal cell-derived factor 1α mediates neural progenitor cell motility after focal cerebral ischemiaRobin et al., 2006
View HTML- Document ID
- 16931085209708232232
- Author
- Robin A
- Zhang Z
- Wang L
- Zhang R
- Katakowski M
- Zhang L
- Wang Y
- Zhang C
- Chopp M
- Publication year
- Publication venue
- Journal of Cerebral Blood Flow & Metabolism
External Links
Snippet
In the adult rodent, stroke induces an increase in endogenous neural progenitor cell (NPC) proliferation in the subventricular zone (SVZ) and neuroblasts migrate towards the ischemic boundary. We investigated the role of stromal cell-derived factor 1α (SDF-1α) in mediating …
- 210000000130 stem cell 0 title abstract description 33
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Robin et al. | Stromal cell-derived factor 1α mediates neural progenitor cell motility after focal cerebral ischemia | |
| Joy et al. | CCR5 is a therapeutic target for recovery after stroke and traumatic brain injury | |
| Liauw et al. | Thrombospondins 1 and 2 are necessary for synaptic plasticity and functional recovery after stroke | |
| Yan et al. | Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia | |
| Persidsky et al. | Dysfunction of brain pericytes in chronic neuroinflammation | |
| Mahmood et al. | Marrow stromal cell transplantation after traumatic brain injury promotes cellular proliferation within the brain | |
| Gaceb et al. | Pericytes secrete pro-regenerative molecules in response to platelet-derived growth factor-BB | |
| Winkler et al. | Blood–spinal cord barrier pericyte reductions contribute to increased capillary permeability | |
| Tang et al. | Neural stem cell protects aged rat brain from ischemia–reperfusion injury through neurogenesis and angiogenesis | |
| Jin et al. | Lipocalin-2 deficiency attenuates neuroinflammation and brain injury after transient middle cerebral artery occlusion in mice | |
| Ortega et al. | Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia | |
| Mahmood et al. | Human marrow stromal cell treatment provides long-lasting benefit after traumatic brain injury in rats | |
| Williams et al. | Chemokines in the balance: maintenance of homeostasis and protection at CNS barriers | |
| Stanimirovic et al. | Pathophysiology of the neurovascular unit: disease cause or consequence? | |
| Szmydynger-Chodobska et al. | Posttraumatic invasion of monocytes across the blood—cerebrospinal fluid barrier | |
| Rodriguez-Grande et al. | The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury | |
| Azizi et al. | The potential role of chemokines in Alzheimer’s disease pathogenesis | |
| Cui et al. | Therapeutic benefit of treatment of stroke with simvastatin and human umbilical cord blood cells: neurogenesis, synaptic plasticity, and axon growth | |
| Zhang et al. | Inflammatory activation of human brain endothelial cells by hypoxic astrocytes in vitro is mediated by IL-1β | |
| Lyck et al. | ALCAM (CD166) is involved in extravasation of monocytes rather than T cells across the blood–brain barrier | |
| Liu et al. | Bone marrow stromal cells enhance inter-and intracortical axonal connections after ischemic stroke in adult rats | |
| Gautam et al. | Roles of pericytes in stroke pathogenesis | |
| Jin et al. | Post-ischemic administration of heparin-binding epidermal growth factor-like growth factor (HB-EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in the rat | |
| Beck et al. | Participation of bone marrow-derived cells in long-term repair processes after experimental stroke | |
| Chu et al. | CXCL12/CXCR4/CXCR7 chemokine axis in the central nervous system: therapeutic targets for remyelination in demyelinating diseases |